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Abstract Tau is a major microtubule-associated protein in
brain neurons. Its misfolding and accumulation cause neurode-
generative diseases characterized by brain atrophy and demen-
tia, named tauopathies. Genetic forms are caused by mutations
of microtubule-associated protein tau gene (MAPT). Tau is
expressed also in nonneural tissues such as lymphocytes. Tau
has been recently recognized as amultifunctional protein, and in
particular, some findings supported a role in genome stability. In
fact, peripheral cells of patients affected by frontotemporal
dementia carrying differentMAPT mutations showed structural
and numerical chromosome aberrations. The aim of this study
was to assess chromosome stability in peripheral cell from two
animal models of genetic tauopathy, JNPL3 and PS19 mouse
strains expressing the human tau carrying the P301L and P301S
mutations, respectively, to confirm the previous data on
humans. After demonstrating the presence of mutated tau in
spleen, we performed standard cytogenetic analysis of splenic
lymphocytes from homozygous and hemizygous JNPL3, hemi-
zygous PS19, and relevant controls. Losses and gains of chro-
mosomes (aneuploidy) were evaluated. We detected a signifi-
cantly higher level of aneuploidy in JNPL3 and PS19 than in
control mice. Moreover, in JNPL3, the aneuploidy was higher
in homozygotes than in hemizygotes, demonstrating a gene
dose effect, which appeared also to be age independent. Our
results show that mutated tau is associated with chromosome
instability. It is conceivable to hypothesize that in genetic
tauopathies the aneuploidy may be present also in central ner-
vous system, possibly contributing to neurodegeneration.
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Introduction
Tauopathies are neurodegenerative diseases caused by accu-
mulation of filamentous and hyperphosphorylated tau protein
in nerve and glial cells of the central nervous system, giving
rise to brain atrophy and dementia. Tau belongs to the family
of microtubule-associated proteins (MAPs), which regulate
microtubule polymerization and dynamics. Tau is the major
MAP in brain neurons, but it is also expressed in nonneural
tissues such as lymphocytes and fibroblasts [1–3].
Recent findings pointed to new functions of tau besides its
traditionally recognized role in neuronal morphogenesis and
axonal transport [4]. In particular, a relationship between tau
and DNA/chromosomes has emerged. The presence of tau in
interphasic nucleoli and in the nucleolar organizer regions of
mitotic acrocentric chromosomes has suggested a role in
ribosome RNA biogenesis [2, 5]. The in vitro ability of tau
to efficiently bind to DNA, preventing it from oxidative
damage [6], and the in vivo recruitment of tau into the nucleus
and its binding to chromatin during heat stress [7] supported
its involvement as DNA-protecting chaperone protein. Very
recently, a role of tau in chromosome stability has also been
advanced, based on the presence of chromosome aberrations
in cells from patients affected by frontotemporal dementia
carrying different tau mutations, including the P301L [3, 8],
and in cells derived from tau knockout mice [9].
Genetic tauopathies are caused by mutations in the
microtubule-associated protein tau gene (MAPT). These mu-
tations either reduce the ability of tau to promote the
G. Rossi (*) : L. Paoletta : E. Piccoli :M. G. Ferretti :
M. Mangieri :M. Ruggerone : F. Tagliavini
Division of Neurology Vand Neuropathology, Fondazione IRCCS
Istituto Neurologico Carlo Besta, 20133 Milan, Italy
e-mail: grossi@istituto-besta.it
D. Conconi : E. Panzeri : L. Dalprà
Department of Neurosciences and Biomedical Technologies,
Milano-Bicocca University, 20052 Monza, Italy
L. Dalprà




microtubule polymerization or alter the physiological ratio of
different tau isoforms, leading to production of tau deposits
and cytoskeleton disruption [10].
Several animal models of genetic tauopathies have been
generated since the discovery of the first mutations inMAPT.
One of the first and most studied mutations in patients affected
by tauopathy is the P301L. Transgenic mice expressing the
human tau carrying the P301L mutation (JNPL3 strain) have
been widely described at clinical, neuropathological, and bio-
chemical level [11–13].
In this study, we first investigated the presence of chromo-
some aberrations, in particular aneuploidy, in the JNPL3
mouse model, to confirm and extend results from humans
[3, 8]. Cytogenetic analysis of lymphocytes from hemyzygous
and homozygous JNPL3 and control mice showed
chromosome instability linked to the P301L mutation. This
instability appeared to be dependent on gene dosage and
independent from disease status. We then analyzed an addi-
tional mouse model, PS19 expressing the human tau carrying
the P301S mutation [14], and confirmed the presence of
aneuploidy in lymphocytes. Thus, MAPT mutations appear
to be associated with chromosome instability.
Materials and methods
Mouse strains
JNPL3 Transgenic mouse strain JNPL3 expresses human tau
(isoform 0N4R, containing four microtubule-binding repeats
Fig. 1 Analysis of expression of
tau protein in JNPL3 and control
mice. a Human MAPT mRNA
analysis. Agarose gel
electrophoresis showing the
products of RT-PCR spanning the
mutated region. Lanes 2–4
DNAse-treated samples; lanes 5–
7 DNAse- and RNAse-treated
samples. b , c , e , f Western blot
analysis of tau present in brain,
spleen, and isolated lymphocytes.
b Tissue homogenates. c
Immunoprecipitated tau.
Numbers at the bottom indicate
micrograms of total proteins
loaded. d Tubulin revealed by
DM1A antibody, in the same
samples as in b . e , f Comparison
of expression levels of tau in
different strains in spleen (e) and
lymphocytes (f); 200 μg of total
proteins were loaded in each lane.
For tau detection, blots were
developed with RD4 antibody.
Ho homozygous, He
hemizygous, C control
(B6D2F1), b brain, s spleen
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and lacking exons 2 and 3) carrying the P301L mutation [11].
Wild-type (wt) non-transgenic strain B6D2F1 was used to
maintain hemizygous JNPL3 by breeding.
For cytogenetic analysis, we used both hemizygous and
homozygous JNPL3 and, as negative controls, their negative
littermates, B6D2F1 and JN25. The latter (gift from J. Lewis)
is a transgenic strain expressing the identical (but wt) tau
isoform at the same level as JNPL3 strain [11]. JN25 mice
were used only as hemizygotes because homozygosis was
lethal at about 3 weeks of age for unknown reasons. Homo-
zygous and hemizygous JNPL3 were sacrificed at different
ages, corresponding to presymptomatic, early symptomatic,
and fully symptomatic stages of the disease; negative controls
were sacrificed at matching ages.
JNPL3 mice were assessed weekly for the presence of
motor and behavioral dysfunctions. Evaluation of activity
level, arousal, posture, gait, and occurrence of involuntary
motor movements was performed. In the early symptomatic
stage, animals showed a reduction of escape extension. Pro-
gression of symptoms included hunched posture, tremors, leg
scissoring, decrease of hind limb tone, and loss of weight. In
the latest stage, the ability to ambulate was reduced, resulting
in paraparesis with lateral recumbency in some animals.
PS19 Transgenic mouse strain PS19 expresses human tau
(isoform 1N4R, containing four microtubule-binding repeats
and lacking exon 3) carrying the P301Smutation [14].Wt non-
transgenic strain B6C3F1 was used to maintain hemizygous
PS19 by breeding. Thesemice cannot be bred to homozygosity.
For cytogenetic analysis, we used hemizygous PS19 and their
negative littermates as negative controls. PS19 were sacrificed
from 2 to 4 months of age, at presymptomatic stage of the
disease; negative controls were sacrificed at matching ages.
Human MAPT mRNA expression
Total RNA was isolated from brain and spleen with the
QIAamp RNA blood mini kit (Qiagen). We treated RNAwith
DNAse (Ambion) to remove DNA before reverse transcribing
it with random primers using cloned AMV First-Strand Syn-
thesis Kit (Invitrogen). A 485-bp fragment comprising the
mutated region was obtained by PCR using primers specific
to MAPT cDNA. PCR fragments were visualized by electro-
phoresis on agarose gel and then subjected to direct sequenc-
ing. In an additional set of samples, we used RNAse on
DNAse-treated RNA samples before reverse transcription, to
exclude the amplification product could have derived from
traces of undigested original MAPT cDNA.
Biochemical analysis of tau protein
Tissue homogenates Samples of brain or spleen were homog-
enized in nine volumes of lysis buffer (10 mM Tris–HCl, pH
Fig. 2 Presence of nuclear tau in spleen. a Western blot analysis of tau
present in total tissue homogenates (lanes 1 and 2) and cytosolic (lanes 3
and 5) or nuclear (lanes 4 and 6) fractions from homozygous JNPL3 and
control mice. Two hundred micrograms of tissue homogenate were loaded
in lanes 1 and 2; 200 μg of cytosolic fraction were loaded in lanes 3 and 5;
nuclear fraction was threefold concentrated, thus corresponding to 600 μg
of cytosolic fraction. Blots were developedwith RD4 antibody. b The same
subcellular fractions probed with anti-lamin B1 (lanes 1–4) or anti-tubulin
(lanes 5–8) antibodies, showing lack of cross-contamination. J homozy-
gous JNPL3, C control, hom tissue homogenate, cyt cytosol, nucl nucleus
Table 1 Summary of analyzed data and cytogenetics results
Strain N animals N metaphases % loss (N /total) % gain (N /total) Total % (N /total)
Total Mean/animal
Homozygous JNPL3 26 1,549 60 29.8 (462/1,549) 5.2 (81/1,549) 35.0 (543/1,549)
Hemizygous JNPL3 22 1,017 46 20.3 (206/1,017) 1.7 (17/1,017) 22.0 (223/1,017)
JN25 21 961 46 10.3 (99/961) 2.2 (21/961) 12.5 (120/961)
Negative littermates/B6D2F1 22 1,074 49 12.1 (130/1,074) 1.6 (17/1,074) 13.7 (147/1,074)
% loss the percentage of metaphases with chromosome loss,% gain the percentage of metaphases with chromosome gain, total % total percentage of
aneuploidy (sum of losses and gains), N number
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Fig. 3 Examples of aneuploid
metaphases. Reconstructed
karyotypes showing monosomy
of chromosome 3 (a) and 12 (b)
and trisomy of chromosome 11
(c)
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7.4, 100mMNaCl, 10mMEDTA, 0.5 %Nonidet P-40, 0.5%
sodium deoxycholate), briefly sonicated, and clarified by cen-
trifugation at 16,000×g for 3 min. The total protein content
was quantified by BCA assay (Pierce).
Immunoprecipitation Tau protein was concentrated by immu-
noprecipitation with the phosphorylation-independent poly-
clonal anti-Tau antibody (Sigma), using the Protein G Mag
Sepharose kit (GE Healthcare). Briefly, 400 μg of tissue
homogenate was added to 15 μl of antibody after crosslinking
to the beads, in 1 ml final volume of PBS buffer. Tau protein
was eluted in 50 μl sample buffer.
Subcellular fractionation Subcellular fractionation was
performed on tissue homogenate according to de Barreda
et al. [15] with minor modifications.
Lymphocyte isolation Blood lymphocytes were isolated by
stratifying whole blood on Ficoll-Paque Plus (GEHealthcare).
After centrifugation on Ficoll-Paque, lymphocytes were re-
covered, washed with PBS, homogenized in lysis buffer, and
their protein content determined as above.
Western blot analysis Protein extracts were dissolved in
sodium dodecyl sulfate (SDS) sample buffer (50 mM
Tris–HCl, pH 6.8, 100 mM β-mercaptoethanol, 2 %
SDS, 0.1 % bromophenol blue, 10 % glycerol), subjected to
10 % SDS–polyacrylamide gel electrophoresis, transferred
to polyvinylidene difluoride membranes (Immobilon,
Millipore), and probed with the following monoclonal anti-
bodies: four-repeat isoform RD4, recognizing tau isoforms
carrying four microtubule-binding repeats (Millipore,
1:1000); DM1A, raised against alpha-tubulin, used as cyto-
plasmic marker (Sigma, 1:1000); and antibody to lamin B1,
used as nuclear marker (Santa Cruz, 1:200). Immunoreactive
bands were visualized by enhanced chemiluminescence (GE
Healthcare).
Culture of splenic lymphocytes and cytogenetic analysis
Spleens were removed aseptically, placed in RPMI 1640
medium supplemented with 10 % fetal calf serum, homoge-
nized, and filtered through a cell strainer to obtain a free cell
suspension. This suspension was cultured in the above
Fig. 4 Total levels of aneuploidy in splenic lymphocytes. a Distributions and b means and standard deviations of the percentages of aneuploidy (sum of
losses and gains). Asterisks indicate significant differences (p<<0.001; Student’s t test)
Fig. 5 Distribution of the percentages of loss or gain among all the chromosomes. a Loss. b Gain. The actual percentages of loss or gain for each
genotype are reported in Table 1; in this graph, they are assumed as 100 %. Z marker chromosome
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medium added with 5 μg/ml concanavalin A for 42 h and then
treated with colcemid for 45 min before cell harvesting. Hy-
potonic treatment in 75 mM KCl for 20 min at 37 °C was
followed by fixation with 3:1 methanol/acetic acid for 30 min
on ice. Cells were then dropped onto glass slides and left to
dry. Karyotype was analyzed by QFQ banding (Chromowin
software, Tesi Imaging) according to the guidelines of Mouse
Genome Database [16]. All chromosome spread scores were
performed by two independent operators.
Statistical methods




Molecular and biochemical analysis In JNPL3, the human
MAPT cDNA carrying the P301Lmutation is expressed under
the control of the mouse prion protein promoter [11]. This
promoter is not tissue restricted. To verify the presence of
mutated tau in the spleen, the peripheral tissue we chose for
cytogenetic analysis, we analyzed both RNA and protein
expression (Fig. 1).
Total RNA was extracted from the brain and spleen of
homozygous JNPL3 and from the spleen of B6D2F1 mice.
After RT-PCR, amplification products were detected only in
the brain and spleen from JNPL3 (Fig. 1a, lanes 2 and 3),
while the control mice did not amplify (Fig. 1a, lane 4). By
direct sequencing, these PCR fragments showed exclusively
the mutated codon CTG corresponding to 301L (not shown).
In the set of samples subjected to RNAse, no amplification
was detected (Fig. 1a, lanes 5–7), confirming that the above-
described amplification was derived only from RNA. These
results demonstrated the expression of transgenic tau in
spleen, apparently at a lower level than in brain (compare
lanes 2 and 3).
Endogenous tau was present in the spleen from control
mice (Fig. 1b, lanes 4 and 5; Fig. 1c, lane 2). A much higher
amount of tau was detected in JNPL3 mice (Fig. 1b, lanes 2
and 3; Fig. 1c, lane 1), clearly due to the additional expression
of transgenic human tau. Endogenous and transgenic proteins
migrated with similar molecular weight. Immunoprecipitation
partially purified and enhanced the amount of tau loaded in the
gel (compare Fig. 1b, lanes 3 and 4, to Fig. 1c). RD4 antibody
detected only tau isoforms with four repeats, in particular
transgenic tau, in addition to endogenous tau isoforms. The
anti-tubulin antibody showed the same amount of total pro-
teins loaded in JNPL3 and control samples (Fig. 1d).
The level of tau in spleen was similar for hemizygous
JNPL3 and JN25, as previously reported [11] (Fig. 1e). This
made JN25 a good control for JNPL3. Further biochemical
analysis on purified lymphocytes demonstrated the expression
of tau in these cells (Fig. 1f).
Since tau has been recently recognized as a nuclear protein,
we verified this finding on subcellular fractions and demon-
strated the presence of nuclear tau in the spleen of JNPL3 and
control mice (Fig. 2). The amount of nuclear tau is higher in
JNPL3, accordingly to results shown in Fig. 1.
Fig. 6 Levels of aneuploidy in splenic lymphocytes: comparison among
different stages of the disease. a Distribution and b means and standard
deviations of the percentages of aneuploidy (sum of losses and gains).
Asterisks indicate significant differences (p <<0.001; Student’s t test).
Significant differences are only between homozygotes and hemizygotes,
as previously depicted in Fig. 4
Fig. 7 Analysis of expression of tau protein in PS19 and control mice. a
HumanMAPT mRNA analysis. Agarose gel electrophoresis showing the
products of RT-PCR spanning the mutated region. Lane 2 : brain; lane 3 :
spleen. b , c Western blot analysis of tau present in spleen (b) and isolated
lymphocytes (c); 200 μg of total proteins were loaded in each lane. Blots
were developed with RD4 antibody. C control (B6C3F1)
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Cytogenetic analysis Table 1 summarizes data regarding an-
alyzed animals and results from cytogenetic analysis. Figure 3
shows examples of aneuploid metaphases. The analysis re-
vealed a low percentage of aneuploid cells that was similar
(p =0.60) in wt (B6D2F1 and negative littermates, mean ±
SD=13.7±5.7) and JN25 (mean ± SD=12.5±6.5) mice.
JNPL3 mice showed a significantly higher level of aneuploi-
dy, which was more pronounced in homozygotes (mean ±
SD=35.0±9.8) than in hemizygotes (mean ± SD=22±7.5)
(Fig. 4). Chromosome losses prevailed over gains (Table 1)
and both of them were evenly distributed among all chromo-
somes without preference (Fig. 5).
We also divided JNPL3, both homozygous and hemizy-
gous, into three groups based on the clinical stage of disease
(presymptomatic, early symptomatic, and fully symptomatic)
and compared the respective levels of aneuploidy (Fig. 6). No
differences were found among the groups (p values ranged
from 0.19 to 0.96), suggesting that aneuploidy is a phenome-
non independent from the stage of disease, depending rather on
the genetic status (wt or mutated tau). This was also confirmed
by the significantly higher level of aneuploidy in homozygous
than in hemizygous JNPL3, revealing a gene dosage effect.
PS19
We decided to analyze this additional mouse model of genetic
tauopathy in order to determine the presence of chromosome
aberrations in association with a different tau mutation.
Molecular and biochemical analysis In PS19, the human
MAPT cDNA carrying the P301Smutation is expressed under
the control of the same mouse prion protein promoter as for
JNPL3 [11, 14, 19]. Thus, we expected tau was expressed in
spleen. In fact, RNA analysis showed the expression of the
transgene in spleen, although at a lower level than in brain
(Fig. 7a). RNAse treatment of DNAse-treated RNA gives no
amplification (not shown). Sequencing of amplified fragments
showed exclusively the mutated codon TCG corresponding to
301S (not shown).
Endogenous tau was present in spleen from control mice
and a higher amount of tau was detected in PS19 mice
(Fig. 7b), due to the additional expression of transgenic human
tau. The same findings were present in isolated lymphocytes
(Fig. 7c).
Cytogenetic analysis Results showed a higher percentage of
aneuploid cells in PS19 (mean ± SD=17.4±8.7) than in
controls (mean ± SD=6.4±5.2) (Table 2 and Fig. 8). Chro-
mosome losses prevailed over gains (Table 2) and were dis-
tributed among all chromosomes (Fig. 9). Losses of four
chromosomes (4, 9, 12, 19) were detected only in PS19.
Chromosome gains showed no overlap between PS19 and
controls, except for marker chromosomes.
Discussion
Tau is well known as a cytoskeletal protein which interacts
with microtubules and regulates their formation and dynam-
ics. In the nervous system, tau has a role in neuron morpho-
genesis and axonal transport and has been characterized as
major misfolded protein involved in the pathogenesis of
Fig. 8 Total levels of aneuploidy
in splenic lymphocytes. a
Distributions and b means and
standard deviations of the
percentages of aneuploidy (sum
of losses and gains). Asterisk
indicates significant difference
(p =0.002; Student’s t test)
Table 2 Summary of analyzed data and cytogenetics results
Strain N animals N metaphases % loss (N /total) % gain (N /total) Total % (N /total)
Total Mean/animal
Hemizygous PS19 13 650 50 15.1 (98/650) 2.3 (15/650) 17.4 (113/650)
Negative littermates 10 500 50 5.4 (27/500) 1.0 (5/500) 6.4 (32/500)
% loss the percentage of metaphases with chromosome loss,% gain the percentage of metaphases with chromosome gain, total % total percentage of
aneuploidy (sum of losses and gains), N number
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Alzheimer’s disease and frontotemporal dementia. Presently,
tau is regarded as multifunctional protein, with a role in
ribosome biogenesis and signal transduction [4], this latter
function possibly being connected to amyloid-beta toxicity
in Alzheimer’s disease [17].
A recent and previously unrecognized function of tau
in genome stability has also been suggested. In fact, the
protein has the ability to interact with DNA in vitro,
protecting it from oxidative stress [6, 18], and with
chromatin in vivo preventing DNA damage caused by
heat stress [7]. Tau involvement in chromosome stability
has been advanced based on the findings of structural
and numerical chromosome aberrations and chromatin
and spindle abnormalities in cells from patients affected
by frontotemporal dementia carrying different tau muta-
tions [3, 8], as well as by the presence of chromosome
aberrations in cells from tau knockout mice [9]. We
hypothesize that tau affects genome stability due to (a)
its role as a MAP, localized in particular on mitotic
spindle where it influences correct dynamics and chro-
mosome segregation, and (b) its presence in the nucleus,
associated with chromatin, affecting DNA integrity. As
a result, mutations in tau protein can alter its function
and lead to genome instability.
To confirm and widen our previous findings in humans, in
this study, we used two animal models of tauopathy. We first
chose the JNPL3 strain expressing the P301L mutation be-
cause of our earlier observation of chromosome aberrations in
patients carrying the same mutation [3, 8] and the availability
of large amount of clinical and neuropathological data on
these mice. After obtaining significant findings about chro-
mosome instability in JNPL3 mice, we performed the same
analyses on PS19 mice.
In JNPL3 mice, the transgene is under the control of mouse
prion promoter [11], which is not tissue restricted, thus
allowing the transgene expression in all tissues. However,
the expression is variable and can be dependent on transgene
itself [19]. We then assessed the expression of transgenic tau
in the peripheral tissue we decided to use for cytogenetic
analysis, i.e., the spleen. We used splenic instead of peripheral
blood lymphocytes since the former have a greater ability to
divide and grow in vitro, enabling the cytogenetic analysis of
mitotic chromosome spreads, paralleling the previous analysis
on human subjects. By analysis of RNA and protein expres-
sion, we actually demonstrated the presence of mutated tau in
the spleen, although at lower level than in the brain. In
addition, we demonstrated the expression of tau in isolated
blood lymphocytes. We confirmed the expression of tau in
spleen and lymphocytes of PS19, as expected because of the
use of the same promoter as in JNPL3.
We detected tau not only in the cytoplasmic, but also in the
nuclear fraction of splenic cells. Evidence of both cytoplasmic
and nuclear tau was given some years ago in neuroblastoma
cell lines [20, 21] and very recently in primary cultures of
mouse neurons [7, 15]. In our opinion, nuclear localization of
tau is very important for preserving genome stability by
physical interaction with chromatin and DNA.
As negative controls for JNPL3, in addition to the B6D2F1
mouse strain and negative littermates originating from breed-
ing JNPL3 and B6D2F1 mice, we also used the JN25 strain
because it expresses the identical but wt tau isoform at the
same level than JNPL3 mice [11]. This allowed to assign any
phenotypes present in JNPL3mice to the mutation itself rather
than to transgene expression levels.
JN25 mice were only described in the original paper from
Lewis et al., where it was not specified if they were
hemizygotes or homozygotes. After embryo revitalization,
we produced hemizygous mice, which did not show any
pathological phenotype, but we were not able to grow homo-
zygous mice, since they all died at about 3 weeks of age.
Hypotheses that can be considered to explain this lethality are
that (a) the site of transgene insertion is very critical for
survival and its disruption is not tolerated in homozygous
state, or (b) the revitalization process itself has introduced a
Fig. 9 Distribution of the
percentages of loss or gain among
all the chromosomes. a Loss; b
Gain. The actual percentages of
loss or gain for each genotype are
reported in Table 2; in this graph,
they are assumed as 100 %. Z
marker chromosome
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defect which is lethal in homozygotes. So, we only used
hemizygous JN25 for cytogenetic analysis.
We found significantly higher percentages of aneuploidy in
JNPL3 and PS19 mice than in their controls. This result is in
agreement with the finding that tau carrying the P301L muta-
tion influences microtubule dynamics, giving rise to overly
dynamic microtubules [22]. This may affect proper chromo-
some segregation, leading to aneuploidy. This effect may also
be true for the P301S mutation. A relatively low aneuploidy
level was detected in controls of JNPL3 (13.7 % of aneuploid
cells in wt and 12.5 % in JN25), in accordance with previous
findings of a mean aneuploid level of about 13 % in splenic
lymphocytes of non-transgenic mice [9]. In controls of PS19
(B6C3F1) the aneuploidy level was lower (6.6 %), probably
depending on the genetic background. Thus, a low aneuploidy
level should be considered as a normal, intrinsic phenomenon,
consistent with a normal phenotype.
The higher percentages of aneuploid cells in JNPL3 mice
(35.0 % and 22.0 % in homozygotes and hemizygotes, re-
spectively) can thus be attributed to the presence of mutated
tau. Particularly relevant was the difference between JNPL3
and JN25mice because it can only be ascribed to the mutation.
In addition, aneuploidy was dependent on gene dosage, as
homozygotes had a higher level than hemizygotes. Aneuploi-
dy seems to be a precocious effect, as it was present in
presymptomatic animals, and no increase in aneuploidy level
was detected with age, excluding a progressive accumulation;
accordingly, no positive correlation was found between pro-
gression of disease and aneuploidy level.
The prevalence of chromosome losses over chromosome
gains may only partially be attributed to a technical bias, being
present in control mice. However, the significantly higher
percentages of losses in JNPL3 and PS19 than in the control
mice suggest that mutated tau (as a MAP) causes true chro-
mosome losses. Mutated tau preferably would produce aneu-
ploidy through the mechanism of anaphase lagging, which
results in both euploid and monosomic cells (loss only), rather
than through the mechanism of non-disjunction, which results
in abnormal cells, both monosomic and trisomic.
The higher percentage of aneuploid cells in JNPL3 and
PS19 mice did not cause pathological phenotype such as
tumor growth. We found no tumor susceptibility of JNPL3
or PS19 with respect to control mice.We think this aneuploidy
may not be sufficient per se to induce tumors, necessitating
other genetic and/or environmental causative events.
There is of course the possibility that the transgenic mutat-
ed MAPT has integrated into and disrupted a locus important
for correct chromosome segregation. Several genes having a
role in spindle assembly checkpoint, centrosome constitution,
microtubule dynamics, or chromosome cohesion are involved
in chromosome segregation. Disruption of one of them can
lead to aneuploidy. We do not exclude this possibility; how-
ever, it is highly unlikely that this “unfortunate” integration
should just happen in two different unrelated animal models
carrying a MAPT mutation and not in a third one (JN25)
carrying wt MAPT. In addition, it is very interesting and
intriguing the fact that tau protein is a microtubule-associated
protein, present also on mitotic spindle, and then it may
contribute per se to chromosome segregation.
High levels of aneuploidy were recently detected in neu-
rons of transgenic mice carrying an APP mutation [9] as well
as in the brains from patients affected by Alzheimer’s disease
and ataxia telangiectasia [23]. It would be very interesting to
investigate whether the same scenario occurs in primary
tauopathies and, if so, to search for a contribution of aneu-
ploidy to neurodegeneration.
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